Non-steroidal Anti-inflammatory Drug Use and Risk of Age-Related Macular Degeneration in the California Teachers Study
Purpose The aim of this study was to examine whether use of regular aspirin and/or other non-steroidal anti-inflammatory drugs (NSAIDs) is associated with the development of age-related macular degeneration (AMD). Methods In the California Teachers Study cohort (N = 88,481) we identified diagnoses of AMD up to December 31, 2012 by linkage to statewide hospital discharge records. Aspirin, ibuprofen, other NSAIDs, and acetaminophen use and comprehensive risk factor information were collected via self-administered questionnaires at baseline in 1995–1996 and a follow-up questionnaire in 2005–2006. We employed Cox proportional hazard regression to model AMD risk. Results We did not find any associations between AMD and frequency and duration of aspirin or ibuprofen use reported at baseline. In the subsample with more specific information on medication use, we observed a 20% decrease in risk of AMD among low-dose aspirin users (HR 0.81, 95% CI 0.70–0.95) and a 55% decrease among cyclooxygenase-2 (COX-2) inhibitor users (HR 0.45, 95% CI 0.26–0.78) during 6.3 years of average follow-up. Conclusion The decrease in risk of intermediate- or late-stage AMD among women who reported regular use of low-dose aspirin or specific COX-2 inhibitors suggests a possible protective role for medications with COX-2 inhibitory properties or aspirin at doses used for cardiovascular disease prevention..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
---|---|
Enthalten in: |
Drugs & aging - 38(2021), 9 vom: 26. Juli, Seite 817-828 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Xu, Xiaoqing [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Anmerkungen: |
© The Author(s) 2021 |
---|
doi: |
10.1007/s40266-021-00885-z |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR045002851 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR045002851 | ||
003 | DE-627 | ||
005 | 20230519212657.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210906s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s40266-021-00885-z |2 doi | |
035 | |a (DE-627)SPR045002851 | ||
035 | |a (SPR)s40266-021-00885-z-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q ASE |
100 | 1 | |a Xu, Xiaoqing |e verfasserin |4 aut | |
245 | 1 | 0 | |a Non-steroidal Anti-inflammatory Drug Use and Risk of Age-Related Macular Degeneration in the California Teachers Study |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s) 2021 | ||
520 | |a Purpose The aim of this study was to examine whether use of regular aspirin and/or other non-steroidal anti-inflammatory drugs (NSAIDs) is associated with the development of age-related macular degeneration (AMD). Methods In the California Teachers Study cohort (N = 88,481) we identified diagnoses of AMD up to December 31, 2012 by linkage to statewide hospital discharge records. Aspirin, ibuprofen, other NSAIDs, and acetaminophen use and comprehensive risk factor information were collected via self-administered questionnaires at baseline in 1995–1996 and a follow-up questionnaire in 2005–2006. We employed Cox proportional hazard regression to model AMD risk. Results We did not find any associations between AMD and frequency and duration of aspirin or ibuprofen use reported at baseline. In the subsample with more specific information on medication use, we observed a 20% decrease in risk of AMD among low-dose aspirin users (HR 0.81, 95% CI 0.70–0.95) and a 55% decrease among cyclooxygenase-2 (COX-2) inhibitor users (HR 0.45, 95% CI 0.26–0.78) during 6.3 years of average follow-up. Conclusion The decrease in risk of intermediate- or late-stage AMD among women who reported regular use of low-dose aspirin or specific COX-2 inhibitors suggests a possible protective role for medications with COX-2 inhibitory properties or aspirin at doses used for cardiovascular disease prevention. | ||
700 | 1 | |a Ritz, Beate |e verfasserin |4 aut | |
700 | 1 | |a Coleman, Anne L. |e verfasserin |4 aut | |
700 | 1 | |a Liew, Zeyan |e verfasserin |4 aut | |
700 | 1 | |a Deapen, Dennis |e verfasserin |4 aut | |
700 | 1 | |a Lee, Eunjung |e verfasserin |4 aut | |
700 | 1 | |a Bernstein, Leslie |e verfasserin |4 aut | |
700 | 1 | |a Pinder, Rich |e verfasserin |4 aut | |
700 | 1 | |a Marshall, Sarah F. |e verfasserin |4 aut | |
700 | 1 | |a Heck, Julia E. |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Drugs & aging |d Berlin [u.a.] : Springer, 1991 |g 38(2021), 9 vom: 26. Juli, Seite 817-828 |w (DE-627)SPR033224900 |w (DE-600)2043689-0 |x 1179-1969 |7 nnns |
773 | 1 | 8 | |g volume:38 |g year:2021 |g number:9 |g day:26 |g month:07 |g pages:817-828 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40266-021-00885-z |z kostenfrei |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OPC-PHA | ||
912 | |a SSG-OPC-ASE | ||
951 | |a AR | ||
952 | |d 38 |j 2021 |e 9 |b 26 |c 07 |h 817-828 |